NEW YORK (360Dx) – BioAffinity Technologies has begun clinical validation of a test for the early detection of lung cancer that uses flow cytometry and detects porphyrin molecules in sputum samples.
The San Antonio-based firm anticipates that its CyPath Lung diagnostic assay will be available as a laboratory-developed test from a CLIA-certified laboratory early next year, and is in discussion with an undisclosed lab that wants to license the technology, its CEO Maria Zannes said in an interview.